Redx, the clinical-stage biotechnology drug discovery company, has announced that Sarah Gordon-Wild has resigned from her role as an independent non-executive director on the board.

Experienced industry analyst Gordon-Wild, who was first appointed in June 2020, has cited ‘personal reasons’ for her decision and will leave at the end of the company’s current financial year on September 30.

Dr Jane Griffiths, chair of the board, said: “On behalf of the board, I would like to thank Sarah for her significant contribution over the last three years and for her ongoing commitment to the company as a shareholder. We wish her all the best in her future endeavours.”

Gordon-Wild currently holds 1,316,587 shares in Redx, representing 0.39 per cent of the company’s issued share capital, and intends to remain as a shareholder.

Drug development company Redx Pharma to merge with US firm

At this time, the Cheshire-based Redx does not intend to appoint a replacement independent non-executive director.

Gordon-Wild is currently chair of the remuneration committee and a member of the audit committee of the board.

Following her resignation becoming effective, it is intended that Bernhard Kirschbaum will be appointed chair of the remuneration committee.

The board does not currently intend to appoint a replacement director for Gordon-Wild to either committee.

Earlier this year Redx Pharma announced it was to merge with US drug research company Jounce Therapeutics.

Redx is focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic diseases and the emerging area of cancer-associated fibrosis.

AIM-listed MedTech Redx raises £25.5m